Bioxcel Therapeutics Inc's Customers Performance

Name: Bioxcel Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

BTAI

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


BTAI's Source of Revenues		During the corresponding time, Bioxcel Therapeutics Inc recorded a revenue increase by 51.67 % year on year, sequentially revenue fell by -11.65 %. While revenue at the Bioxcel Therapeutics Inc 's corporate clients • List of BTAI Customers

for the same period Bioxcel Therapeutics Inc recorded revenue increase by 51.67 % year on year, sequentially revenue fell by -11.65 %.

• List of BTAI Customers

Bioxcel Therapeutics Inc's Business Units


Single reportable segments		213.19 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Bioxcel Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Bioxcel Therapeutics Inc Contracts

BioXcel Therapeutics Sets New Standards in Agitation Treatment and Cancer Therapy

BioXcel Therapeutics, an innovative biopharmaceutical company, is making significant strides in the treatment of two distinct health challenges: acute agitation associated with bipolar disorders and schizophrenia, as well as metastatic pancreatic ductal adenocarcinoma (PDAC). Recently, the company announced the initiation of its pivotal Phase 3 safety trial, SERENITY At-Home, investigating the use of BXCL501, a sublingual formulation of dexmedetomidine, in an at-home setting to treat agitation.The need for effective treatments for agitation, particularly in home environments, is underscored by the concerning statistic an estimated 23 million agitation episodes occur annually in these settings. The SERENITY...

BXCL701 and KEYTRUDA: Unveiling a Promising Phase 2 Trial for Metastatic Pancreatic Ductal Adenocarcinoma at 2024 ASCO Annual Meeting

BioXcel Thera...

BioXcel Therapeutics Advances with Phase 3 Trial of BXCL501 to Tackle Agitation in Alzheimer's Patients

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer s Dementia

Company plans to initiate trial following recent meeting with FDAIn a significant development aimed at addressing the growing challenges associated with agitation in patients suffering from Alzheimer s dementia, BioXcel Therapeutics has revealed its plan for the TRANQUILITY In-Care Pivotal Phase 3 Trial with the experimental drug BXCL501. The announcement comes on the heels of a recently held meeting between the company and the United States Food and Drug Administration (FDA).Alzheimer s dementia is a devastating neurodegenerative disease that not only a...

BTAI's Stock Performance relative to it's Customers

BTAI's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Bioxcel Therapeutics Inc	1.42	0.68	-75.33	29
SUBTOTAL	0.00	0.00	0.00	-

Sources: Bioxcel Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Bioxcel Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Bioxcel Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.